Renewed focus on cancer: COVID-19 vaccine company BioNTech SE (Nasdaq: BNTX) and Ryvu Therapeutics S.A., located in Krakow (Warsaw Stock Exchange: RVU), a Polish clinical-stage cancer therapeutics development company, announced that the companies have entered into a research collaboration for several multi-target immunotherapy programmes, as well as an exclusive licensing agreement for Ryvu’s STING agonist portfolio as stand-alone small molecules.
https://european-biotechnology.com/wp-content/uploads/2024/04/ryvu_lab-KR151014AB_105.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-12-04 08:41:002024-07-15 13:30:41BioNTech and Ryvu Therapeutics enter into global collaboration
AstraZeneca announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company spezialised in next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer. The acquisition delivers an initial payment of $200m on deal closing, and a further up to $120m in both contingent milestones-based and non-contingent consideration.
SOTIO Biotech a.s. has exercised its first of five exclusive, target-specific options for antibody-drug conjugate (ADC) SOT106 under its agreement with LegoChem Biosciences Inc.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2022-11-29_um_18.21.05.png540960Margarita Milidakis/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMargarita Milidakis2022-11-29 17:50:012024-07-16 12:13:01SOTIO licences first cancer ADC from LegoChem Biosciences
https://european-biotechnology.com/wp-content/uploads/2024/04/V7Founders.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-11-29 11:51:532024-07-16 12:15:38British AI provider raises $33m in Series A financing
BioEcho Life Sciences develops innovative products that drastically improve the quality, convenience, and speed of standard molecular protocols. The EchoLUTION technology consists of an efficient and gentle lysis, followed by a unique single-step centrifugation, which provides a reduction of procedural steps compared to conventional kits, and considerably reduces plastic waste.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB.com_Frank_Mathias_kl.jpg253225Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2022-11-23 10:11:002024-07-16 17:30:36Oxford Biomedica gains new CEO
Houston, Texas Nov. 21, 2022 Sino Biological, Inc. (Sino Biological or the Company), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services, is pleased to announce the formal signing of a lease with Hines and initiation of construction on its new Center for Bioprocessing (C4B) at its Levit Green facility in Houston, Texas USA.
https://european-biotechnology.com/wp-content/uploads/2024/04/Adv_Sino_11_2022.png540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-11-23 00:00:002024-04-02 15:34:33Sino Biological Announces Construction of Its New US-Based Center for Bioprocessing
BioNTech and Ryvu Therapeutics enter into global collaboration
Latest NewsRenewed focus on cancer: COVID-19 vaccine company BioNTech SE (Nasdaq: BNTX) and Ryvu Therapeutics S.A., located in Krakow (Warsaw Stock Exchange: RVU), a Polish clinical-stage cancer therapeutics development company, announced that the companies have entered into a research collaboration for several multi-target immunotherapy programmes, as well as an exclusive licensing agreement for Ryvu’s STING agonist portfolio as stand-alone small molecules.
Amsterdam Neogene Therapeutics aquired by AstraZeneca
Latest NewsAstraZeneca announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company spezialised in next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer. The acquisition delivers an initial payment of $200m on deal closing, and a further up to $120m in both contingent milestones-based and non-contingent consideration.
Novo Nordisk funds API manufacturing with €726m
Latest NewsNovo Nordisk A/S invests €726m to expand facilities and to produce APIs to supply the company’s global clinical trials.
SOTIO licences first cancer ADC from LegoChem Biosciences
Latest NewsSOTIO Biotech a.s. has exercised its first of five exclusive, target-specific options for antibody-drug conjugate (ADC) SOT106 under its agreement with LegoChem Biosciences Inc.
British AI provider raises $33m in Series A financing
Latest NewsLondon-based computer vision specialist V7 Ltd has baged $33m in Series A financing co-led by AI-focused Radical Ventures and Temasek.
Growing investor interest in biotechnology
Latest NewsLatest investment trends were presented by BIOTECH Insight at the start of the German Equity Forum
C4X Discovery Holdings inks $402m deal with AstraZeneca
Latest NewsC4X Discovery Holdings plc has exclusively licenced its NRF2 Activator programme to AstraZeneca and has got an upfront payment of $2m.
Speedy DNA extraction from buccal swabs & FFPE samples
Sponsored PublicationsBioEcho Life Sciences develops innovative products that drastically improve the quality, convenience, and speed of standard molecular protocols. The EchoLUTION technology consists of an efficient and gentle lysis, followed by a unique single-step centrifugation, which provides a reduction of procedural steps compared to conventional kits, and considerably reduces plastic waste.
Oxford Biomedica gains new CEO
AppointmentsDr Frank Mathias, currently CEO at Rentschler Biopharma, will join Oxford Biomedica as CEO and Board Director in March 2023.
Sino Biological Announces Construction of Its New US-Based Center for Bioprocessing
Sponsored PublicationsHouston, Texas Nov. 21, 2022 Sino Biological, Inc. (Sino Biological or the Company), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services, is pleased to announce the formal signing of a lease with Hines and initiation of construction on its new Center for Bioprocessing (C4B) at its Levit Green facility in Houston, Texas USA.